Compare OLP & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OLP | DSGN |
|---|---|---|
| Founded | 1982 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 508.4M | 579.9M |
| IPO Year | 1995 | 2021 |
| Metric | OLP | DSGN |
|---|---|---|
| Price | $22.70 | $10.28 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $27.50 | $15.25 |
| AVG Volume (30 Days) | 61.8K | ★ 242.4K |
| Earning Date | 03-05-2026 | 03-09-2026 |
| Dividend Yield | ★ 7.94% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.15 | N/A |
| Revenue | ★ $82,740,000.00 | N/A |
| Revenue This Year | $7.76 | N/A |
| Revenue Next Year | $4.51 | N/A |
| P/E Ratio | $19.73 | ★ N/A |
| Revenue Growth | ★ 1.02 | N/A |
| 52 Week Low | $19.62 | $2.62 |
| 52 Week High | $26.86 | $11.23 |
| Indicator | OLP | DSGN |
|---|---|---|
| Relative Strength Index (RSI) | 46.99 | 50.78 |
| Support Level | $21.94 | $9.64 |
| Resistance Level | $23.63 | $11.14 |
| Average True Range (ATR) | 0.62 | 0.59 |
| MACD | -0.15 | 0.03 |
| Stochastic Oscillator | 28.78 | 42.21 |
One Liberty Properties Inc is a self-administered and self-managed real estate investment trust. It acquires, owns, and manages a geographically diversified portfolio consisting mainly of industrial and, to a lesser extent, retail properties, many of which are subject to long-term net leases. The trust has approximately one hundred two properties located across several states in the United States of America. A majority of its revenue is generated in the form of rental income.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.